ReviewDiabetes & vascular disease research
The expanding role of peptides in cardiovascular care.
Review in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptides have emerged as key regulators of cardiovascular physiology and increasingly important tools in the diagnosis and management of cardiovascular disease (CVD). Endogenous peptide systems, including natriuretic peptides (NPs), the renin angiotensin system (RAS), and vasopressin, play central roles in maintaining vascular tone, fluid balance, and cardiac remodeling, while their dysregulation contributes to disease progression. Clinically, peptide-based biomarkers such as NPs and copeptin are widely used for diagnosis, risk stratification, and prognostic assessment. Beyond their diagnostic utility, peptides have gained significant attention as therapeutic targets. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiometabolic benefits, including reductions in cardiovascular events and improvements in metabolic profiles. In parallel, advances in peptide engineering have enabled the development of innovative therapeutic strategies, including targeted drug delivery systems, regenerative therapies, and enzyme-responsive biomaterials designed to enhance myocardial repair. This review provides a comprehensive overview of the biological, diagnostic, and therapeutic roles of peptides in cardiovascular medicine. Collectively, these findings highlight the expanding clinical relevance of peptides and their potential to support precision-based approaches in cardiovascular care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.